Cite
HARVARD Citation
Piccart, M. et al. (n.d.). Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer. International journal of gynecological cancer. pp. 144-148. [Online].